Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease
- NPJ Parkinsons Dis. 2024 Mar 14;10(1):59. doi: 10.1038/s41531-024-00657-7.
Affiliations
- 1. Idorsia Pharmaceuticals Ltd, CNS Pharmacology, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. [email protected].
PMID: 38486022
DOI: 10.1038/s41531-024-00657-7
Products
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: α-synucleinResearch Areas: Neurological Disease